Frequencies of maximum grades 3 and 4 side effects per patient
Side effects . | FLAG, n (%) . | ARA-C + G-CSF, n (%) . |
|---|---|---|
| Total | 40 (63) | 41 (59) |
| Hemorrhage | 4 (6) | 4 (6) |
| Liver | 10 (16) | 11 (16) |
| Cutaneous | 3 (4) | 3 (4) |
| Cardiac | 10 (16) | 11 (16) |
| Neurotoxicity | 9 (14) | 2 (3)* |
| Infections | 43 (67) | 40 (58) |
| Septicemia | 35 (55) | 26 (38) |
| Gastrointestinal | 9 (14) | 6 (9) |
Side effects . | FLAG, n (%) . | ARA-C + G-CSF, n (%) . |
|---|---|---|
| Total | 40 (63) | 41 (59) |
| Hemorrhage | 4 (6) | 4 (6) |
| Liver | 10 (16) | 11 (16) |
| Cutaneous | 3 (4) | 3 (4) |
| Cardiac | 10 (16) | 11 (16) |
| Neurotoxicity | 9 (14) | 2 (3)* |
| Infections | 43 (67) | 40 (58) |
| Septicemia | 35 (55) | 26 (38) |
| Gastrointestinal | 9 (14) | 6 (9) |
Study populations: FLAG, n = 64; and ARA-C + G-CSF, n = 69.
P < .05.